Image credit- wilhelmsen.com

RMIT University in Australia has signed a commercial licence agreement with start-up Atmo Biosciences for ingestible sensors developed to measure gases in the gut in order to diagnose gut-related disorders.

Under the terms of the agreement, Atmo will gain exclusive rights to commercialise the gut sensors. RMIT will in turn get royalties from the sale of products by Atmo.

The deal also enables the firm to conduct Phase II clinical trials for the new technology, which is expected to be available in the market within four years.

Designed in the form of an electronic capsule, the gut sensors can identify and measure gaseous biomarkers in real-time, enabling diagnosis of gut disorders and targeted therapy. After ingestion, the sensors transmit data through a handheld device and mobile app to the cloud.

-------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.